yes, hard to believe IMGN's valuation compared to CLDX and SGEN. Either CLDX is waaay overvalued, or IMGN is undervalued. IMGN seems to have a bad management discount that can only be cured by new, strong, proven executive management. This should be all over the evening, prime-time news, but probably won't. The technology works, in the right hands (for development).
No, please read the following paragraph in the news "Kadcyla consists of Roche’s trastuzumab antibody and ImmunoGen’s DM1 cytotoxic agent. The DM1 is attached to the antibody using one of ImmunoGen’s linkers. Roche has global development and commercialization rights for Kadcyla; ImmunoGen is entitled to receive specified milestone payments and royalties on product sales. "
That means IMGN only obtain a very small piece of the whole cake, however, CLDX owns its entire cake, if I did not make any mistake.
I think CLDX has a brighter future